Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 5:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: MenACWY Vaccine Clear all
Completed No phase listed Observational Results available

Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study

NCT02287688
View directory record Official record
Conditions
Meningococcal Disease, Infections, Meningococcal
Interventions
Meningococcal quadrivalent CRM-197 conjugate vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Months to 23 Months
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2019 · Synced Sep 4, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Results available

Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

NCT02285777
View directory record Official record
Conditions
Meningococcal Disease
Interventions
Meningococcal ABCWY, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 19 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Huntsville, Alabama • Jonesboro, Arkansas • Melbourne, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2018 · Synced Sep 4, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

NCT01148017
View directory record Official record
Conditions
Meningococcal Meningitis
Interventions
Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
37 Months to 63 Months
Enrollment
433 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
19
States / cities
Birmingham, Alabama • Downey, California • Oakland, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2017 · Synced Sep 4, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age

NCT04440163
View directory record Official record
Conditions
Meningococcal Vaccine
Interventions
MenABCWY, Saline, Trumenba, MenACWY-CRM
Biological
Lead sponsor
Pfizer
Industry
Eligibility
10 Years to 25 Years
Enrollment
2,431 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
61
States / cities
Birmingham, Alabama • Tempe, Arizona • Banning, California + 49 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 4, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults

NCT04502693
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
rMenB+OMV NZ vaccine, Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY), Placebo, MenABCWY-1, MenABCWY-2, MenABCWY-3
Combination Product · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 25 Years
Enrollment
3,657 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
64
States / cities
Chandler, Arizona • Glendale, Arizona • Jonesboro, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Sep 4, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life

NCT01214837
View directory record Official record
Conditions
Meningococcal Disease, Meningococcal Meningitis
Interventions
MenACWY-CRM, Routine Vaccines
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
55 Days to 89 Days
Enrollment
751 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
37
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Sep 4, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

NCT00806195
View directory record Official record
Conditions
Meningitis, Meningococcal Infection
Interventions
MenACWY-CRM197, DTaP (Diptheria, Tetanus, Pertussis) Vaccine, Hib (Haemophilus influenza b) Vaccine, IPV (Inactivated Polio Vaccine) Vaccine, Pneumococcal conjugate Vaccine, MMR (Measles, Mumps, and Rubella) Vaccine, Varicella Vaccine, Hepatitis A Virus
Biological
Lead sponsor
Novartis
Industry
Eligibility
55 Days to 89 Days
Enrollment
7,744 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
130
States / cities
Birmingham, Alabama • Dothan, Alabama • Tuscon, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2013 · Synced Sep 4, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children

NCT00616421
View directory record Official record
Conditions
Meningococcal Infections
Interventions
MenACWY-CRM, Licensed meningococcal ACWY vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
2 Years to 10 Years
Enrollment
2,907 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
52
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Downey, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2016 · Synced Sep 4, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.

NCT00471081
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Meningococcal vaccine GSK134612
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
9 Months to 9 Months
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
19
States / cities
Birmingham, Alabama • Benton, Arkansas • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Sep 4, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults

NCT00715910
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Nimenrix, Blood sampling
Biological · Procedure
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 30 Years
Enrollment
818 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
10
States / cities
Daly City, California • Fairfield, California • Redwood City, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2014 · Synced Sep 4, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination

NCT02986854
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 55 Years
Enrollment
704 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
36
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 4, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants

NCT00474526
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib, Rotavirus, Pneumococcal 7-valent Conjugate Vaccine, HAV, MMR-V, DTaP
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
2 Months to 2 Months
Enrollment
4,545 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
53
States / cities
Bessemer, Alabama • Birmingham, Alabama • Downey, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2014 · Synced Sep 4, 2026, 5:11 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants

NCT04056117
View directory record Official record
Conditions
Shigellosis
Interventions
Shigella 4V, MenACWY, Rabies, Diphtheria, Tetanus and Pertussis (DTaP), Placebo
Biological
Lead sponsor
LimmaTech Biologics AG
Industry
Eligibility
8 Months to 50 Years
Enrollment
597 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
0
States / cities
Not listed
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 4, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY

NCT01018732
View directory record Official record
Conditions
Meningococcal Disease, Meningococcal Meningitis
Interventions
Novartis Meningococcal (MenACWY-CRM) vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
16 Years to 23 Years
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
3
States / cities
Rochester, Minnesota • Pittsburgh, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 14, 2015 · Synced Sep 4, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

NCT04707391
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
MenABCWY vaccine, Placebo, MenACWY vaccine, MenB vaccine
Combination Product · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 25 Years
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
48
States / cities
Jonesboro, Arkansas • Banning, California • Chula Vista, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 4, 2026, 5:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Increasing Vaccine Uptake Among Adolescents in the Rural South

NCT04999267
View directory record Official record
Conditions
Vaccine Hesitancy
Interventions
INVEST
Other
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Durham, North Carolina • Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 4, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults

NCT01272180
View directory record Official record
Conditions
Invasive Meningococcal Disease
Interventions
Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV., Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV., Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine., Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
10 Years to 25 Years
Enrollment
484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
8
States / cities
Birmingham, Alabama • Madera, California • Paramount, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Sep 4, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months

NCT01000311
View directory record Official record
Conditions
Meningococcal Disease
Interventions
MenACWY-CRM, DTaP-IPV/Hib, HBV, PCV, MMR
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
55 Days to 89 Days
Enrollment
529 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
42
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 4, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

NCT02140762
View directory record Official record
Conditions
Meningococcal Disease
Interventions
MenABCWY, Placebo, MenACWY
Biological · Other
Lead sponsor
Novartis Vaccines
Industry
Eligibility
10 Years to 18 Years
Enrollment
305 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
8
States / cities
Huntsville, Alabama • Jonesboro, Arkansas • Melbourne, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Sep 4, 2026, 5:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Safety of MenACWY-CRM Vaccination in Adolescents

NCT01452464
View directory record Official record
Conditions
Meningococcal Disease
Interventions
MenACWY-CRM
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
11 Years to 21 Years
Enrollment
55,397 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
3
States / cities
Riverside, California • San Diego, California • Valley Annex, 16994 E. Valley Blvd., Fontana, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2015 · Synced Sep 4, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents

NCT00262041
View directory record Official record
Conditions
Prevention of Meningococcal Disease
Interventions
MenACWY-CRM conjugate vaccine, adjuvanted, MenACWY-CRM conjugate vaccine, unadjuvanted, MenACWY polysaccharide vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
11 Years to 17 Years
Enrollment
524 participants
Timeline
2004 – 2006
U.S. locations
3
States / cities
Rochester, Minnesota • Pittsburgh, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Sep 4, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.

NCT01682876
View directory record Official record
Conditions
Meningococcal Disease, Infections, Meningococcal
Interventions
MenACWY-CRM
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Years to 10 Years
Enrollment
715 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
19
States / cities
Birmingham, Alabama • Sacramento, California • Lake Mary, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Sep 4, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)

NCT01992536
View directory record Official record
Conditions
Meningococcal Disease
Interventions
MenABCWY+OMV, MenABCWY+¼OMV, Placebo
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
10 Years to 25 Years
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
8
States / cities
Birmingham, Alabama • Madera, California • Paramount, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Sep 4, 2026, 5:11 AM EDT
Completed No phase listed Observational Results available

A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.

NCT05873751
View directory record Official record
Conditions
Gonorrhea, Chlamydia, Meningococcal Vaccines
Interventions
Trumenba Vaccine, MenACWY Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
15 Years to 30 Years
Enrollment
1,307,378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Sep 4, 2026, 5:11 AM EDT